You are here

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Seoul, , Korea, Democratic People's Republic of
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atrial Fibrillation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients aged 18 years or older on the index date

2. Patients had ≥1 medical claim for AF (refer to Table 1) before or on the index date
with at least one hospitalization or at least two outpatient visits:

3. Patients prescribed aspirin, warfarin, or NOACs during intake period (from July 1,
2015 to November 30, 2016)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients meeting any of the following criteria will not be included in the study.

1. Medical claims indicating diagnosis or procedure for hip/knee replacement surgery
within 6 weeks prior to index date

2. Medical claims indicating a diagnosis code indicative of rheumatic mitral valvular
heart disease, mitral valve stenosis during the 12-month baseline period (Valvular AF
/ Prosthetic heart valves)

3. Medical claims indicating a diagnosis code of VTE (Venous thromboembolism) during the
12-month baseline period

4. Medical claims indicating a diagnosis or procedure code of transient AF, or cardiac
surgery during the 12-month baseline period (Thyrotoxicosis, Hypertrophic
cardiomyopathy, Elective defibrillation, radiofrequency ablation, or left atrial
appendage occlusion)

5. Medical claims indicating a diagnosis code of other conditions during the 12-month
baseline period (End-stage chronic kidney disease / Kidney transplant / Dialysis /
Pericarditis)

6. For the comparison of "NOAC versus NOAC", and "NOAC versus warfarin", patients with
any OACs (apixaban, dabigatran, rivaroxaban, or warfarin) in the pre-index period
(from 1 year prior to the day before index date)

7. For the comparison of "NOAC versus aspirin", patients with following medications in
the pre-index period (from 1 year prior to the day before index date)

- NOAC user: OACs (apixaban, dabigatran, rivaroxaban, warfarin)

- Aspirin user: none

NCT03572972
Pfizer
Active, not recruiting
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now